Coordinated regulation of platelet actin filament barbed ends by gelsolin and capping protein.
Exposure of cryptic actin filament fast growing ends (barbed ends) initiates actin polymerization in stimulated human and mouse platelets. Gelsolin amplifies platelet actin assembly by severing F-actin and increasing the number of barbed ends. Actin filaments in stimulated platelets from transgenic gelsolin-null mice elongate their actin without severing. F-actin barbed end capping activity persists in human platelet extracts, depleted of gelsolin, and the heterodimeric capping protein (CP) accounts for this residual activity. 35% of the approximately 5 microM CP is associated with the insoluble actin cytoskeleton of the resting platelet. Since resting platelets have an F-actin barbed end concentration of approximately 0.5 microM, sufficient CP is bound to cap these ends. CP is released from OG-permeabilized platelets by treatment with phosphatidylinositol 4,5-bisphosphate or through activation of the thrombin receptor. However, the fraction of CP bound to the actin cytoskeleton of thrombin-stimulated mouse and human platelets increases rapidly to approximately 60% within 30 s. In resting platelets from transgenic mice lacking gelsolin, which have 33% more F-actin than gelsolin-positive cells, there is a corresponding increase in the amount of CP associated with the resting cytoskeleton but no change with stimulation. These findings demonstrate an interaction between the two major F-actin barbed end capping proteins of the platelet: gelsolin-dependent severing produces barbed ends that are capped by CP. Phosphatidylinositol 4,5-bisphosphate release of gelsolin and CP from platelet cytoskeleton provides a mechanism for mediating barbed end exposure. After actin assembly, CP reassociates with the new actin cytoskeleton.
Barkalow
K
K
Division of Experimental Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Witke
W
W
Kwiatkowski
D J
DJ
Hartwig
J H
JH
D008841:Actin Cytoskeleton / Q000378:metabolism; D051339:Actin Depolymerizing Factors; D000199:Actins / Q000378:metabolism*; D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D051347:CapZ Actin Capping Protein; D002463:Cell Membrane Permeability; D002645:Chickens; D003285:Contractile Proteins / Q000378:metabolism; D003599:Cytoskeleton / Q000378:metabolism; D051345:Destrin; D064448:Filamins; D018260:Gelsolin / Q000378:metabolism*; D005960:Glucosides / Q000494:pharmacology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D051379:Mice; D008840:Microfilament Proteins / Q000378:metabolism*; D009124:Muscle Proteins; D019269:Phosphatidylinositol 4,5-Diphosphate; D018129:Phosphatidylinositol Phosphates / Q000494:pharmacology; D015539:Platelet Activation; D018179:Receptors, Thrombin / Q000378:metabolism
D051339:Actin Depolymerizing Factors; D000199:Actins; C495842:CAPZA1 protein, human; D051347:CapZ Actin Capping Protein; C495843:Capza1 protein, mouse; C495847:Capza2 protein, mouse; D003285:Contractile Proteins; D051345:Destrin; D064448:Filamins; D018260:Gelsolin; D005960:Glucosides; D008840:Microfilament Proteins; D009124:Muscle Proteins; D019269:Phosphatidylinositol 4,5-Diphosphate; D018129:Phosphatidylinositol Phosphates; D018179:Receptors, Thrombin; C018619:octyl-beta-D-glucoside